Reports and Insights (R&I) has published a new report titled, “Mild Traumatic Brain Injury treatment Market: Opportunity Analysis and Future Assessment 2020 to 2028”
Global Mild Traumatic Brain Injury treatment Market, by Treatment Type (Pain relievers, Diuretics, Anti-seizure drugs, Coma-inducing drugs), By End Users (Hospitals, Clinics, ASCs), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a healthy CAGR for the period between 2020 and 2028.
The global mild traumatic brain injury treatment market in 2020 is estimated for more than US$ 65.8 Mn and expected to reach a value of US$ 93.0 Mn by 2028 with a significant CAGR of 4.4%.
As per the report, the increasing incidence of brain injuries due to accidents and the prevalence of neurodegenerative diseases is attributed to growth in the mild traumatic brain injury treatment market. As per the Department of Neurology, University of California San Francisco, each year 42 million people across the globe suffer from mild traumatic brain injury (MTBI). As per the CDC, the incidence of post-traumatic brain injury exceeds 600 per 100,000 people across the globe.
Some of the established risk factors for mild traumatic brain injury are Alzheimer's disease, Parkinson's disease, chronic traumatic encephalopathy, and amyotrophic lateral sclerosis (ALS). According to the Alzheimer’s Association, Alzheimer’s disease is the 6th leading cause of death in the U.S> and approximately 5.8 million Americans are suffering from Alzheimer’s disease. In 2019, Alzheimer’s and other dementia are estimated to cost the Nation around US$ 290 billion. Mild traumatic brain injury is an acute brain injury resulting from mechanical energy to the head from external physical forces. MTBI is extremely common. It is estimated that 100 to 300 per 100,000 people seek medical attention for MTBI annually worldwide. Improving the treatment-seeking rate would thus push the market growth for mild traumatic brain injury treatment.
Furthermore, Reports and Insights (R&I) Study identifies that specific populations such as contact sport athletes, victims of domestic violence, military personnel, etc. are at high risk for suffering mild traumatic brain injuries. Treatment for mild traumatic brain injury generally includes symptomatic treatment such as for headaches. Pain relievers such as NSAIDs are prescribed to alleviate pain. Diuretics such as hydrochlorothiazide, torsemide, etc. are given to mild traumatic brain injury patients to reduce the number of body fluids which reduces pressure inside the brain.
People with moderate to severe traumatic brain injury are at the risk of seizures. An anti-seizure drug may be given during the first week to avoid any additional brain damage that might be caused by a seizure. Sometimes coma-inducing drugs such as benzodiazepines are given to the patients of mild traumatic brain injury to relieve pressure on the brain. A comatose brain needs less oxygen to function and this is helpful blood vessels are unable to supply brain cells with nutrients and oxygen.
R&I Study identifies some of the key participating players in the mild traumatic brain injury treatment market globally are Sanis Health Inc., Zydus Pharmaceuticals Usa, Inc., Aurobindo Pharma, Cardinal Health, Pfizer Inc., Apotex Corporation, Mylan Institutional Inc., Hoffman La Roche, Valeant Pharmaceuticals, Sandoz (Novartis), etc, among others.
Reports and Insights (R&I) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At R&I we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.
Reports and Insights (R&I)
For Sales Queries: firstname.lastname@example.org
For New Topics and Other Info: email@example.com